Skip to main content

Robert Carnahan Archives

‘DNA’ podcast Season 2 explores COVID, science and trust in communities

Aug. 23, 2021—Listen to Episode 1, Blueprint for a Pandemic-Ready Society, and subscribe on your favorite platform. The first episode of the second season of Vanderbilt University Medical Center’s original podcast series, Vanderbilt Health DNA: Discoveries in Action, tackles bold questions and issues pushed to the surface by COVID-19. This season, the award-winning 10-episode series delves into...

Read more


COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study

Aug. 20, 2021—A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.

Read more


Monoclonal antibody “cocktail” blocks COVID-19 variants: study

Mar. 4, 2021—A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.

Read more


Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19

Jul. 15, 2020—Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.

Read more


Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research

Jun. 9, 2020—After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.

Read more


Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments

Apr. 8, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.

Read more


Researchers developing potential coronavirus antibody therapies

Mar. 23, 2020—Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.

Read more


Carnahan named associate director of Vaccine Center

Feb. 6, 2020—Robert Carnahan, PhD, associate professor of Pediatrics and Radiology and Radiological Sciences, has been appointed associate director of the Vanderbilt Vaccine Center.

Read more


VUMC-led team ‘sprints’ to develop Zika virus treatment

Apr. 11, 2019—In January scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis were given an audacious goal to develop — in 90 days — a protective antibody-based treatment that potentially will stop the spread of the Zika virus.

Read more


VUMC scientists ‘sprint’ to find anti-Zika antibodies

Jan. 24, 2019—Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more